• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Targeting mucin hypersecretion in COVID-19 therapy.针对新冠病毒疾病治疗中的粘蛋白过度分泌问题
Future Med Chem. 2022 May;14(10):681-684. doi: 10.4155/fmc-2021-0111. Epub 2022 Mar 22.
2
A dynamic mucin mRNA signature associates with COVID-19 disease presentation and severity.一种动态黏蛋白 mRNA 标志物与 COVID-19 疾病表现和严重程度相关。
JCI Insight. 2021 Oct 8;6(19):e151777. doi: 10.1172/jci.insight.151777.
3
Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung Disease.新型冠状病毒病肺病中黏液积聚的流行情况和机制。
Am J Respir Crit Care Med. 2022 Dec 1;206(11):1336-1352. doi: 10.1164/rccm.202111-2606OC.
4
Glycosylated extracellular mucin domains protect against SARS-CoV-2 infection at the respiratory surface.糖基化细胞外粘蛋白结构域在呼吸道表面抵抗 SARS-CoV-2 感染。
PLoS Pathog. 2023 Aug 10;19(8):e1011571. doi: 10.1371/journal.ppat.1011571. eCollection 2023 Aug.
5
Defensive Properties of Mucin Glycoproteins during Respiratory Infections-Relevance for SARS-CoV-2.黏液糖蛋白在呼吸道感染中的防御特性——与 SARS-CoV-2 的相关性。
mBio. 2020 Nov 12;11(6):e02374-20. doi: 10.1128/mBio.02374-20.
6
Mucin-Inspired Single-Chain Polymer (MIP) Fibers as Potent SARS-CoV-2 Inhibitors.受粘蛋白启发的单链聚合物（MIP）纤维作为强效的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抑制剂
Angew Chem Int Ed Engl. 2023 Jul 17;62(29):e202304010. doi: 10.1002/anie.202304010. Epub 2023 Jun 14.
7
Mucus targeting as a plausible approach to improve lung function in COVID-19 patients.针对黏液作为改善 COVID-19 患者肺功能的一种可行方法。
Med Hypotheses. 2021 Nov;156:110680. doi: 10.1016/j.mehy.2021.110680. Epub 2021 Sep 15.
8
Mucin signature as a potential tool to predict susceptibility to COVID-19.黏蛋白标志物可作为预测 COVID-19 易感性的潜在工具。
Physiol Rep. 2021 Jan;9(1):e14701. doi: 10.14814/phy2.14701.
9
Dynamic expression of mucins and the genes controlling mucin-type O-glycosylation within the mouse respiratory system.小鼠呼吸系统中黏蛋白及其基因控制的黏蛋白型 O-糖基化的动态表达。
Glycobiology. 2023 Jun 21;33(6):476-489. doi: 10.1093/glycob/cwad031.
10
Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?我们是否应该尝试使用 SARS-CoV-2 解旋酶抑制剂治疗 COVID-19？
Arch Med Res. 2020 Oct;51(7):733-735. doi: 10.1016/j.arcmed.2020.05.024. Epub 2020 May 31.

引用本文的文献

1
Submandibular Gland Pathogenesis Following SARS-CoV-2 Infection and Implications for Xerostomia.感染 SARS-CoV-2 后下颌下腺的发病机制及其对口干症的影响。
Int J Mol Sci. 2024 Jun 21;25(13):6820. doi: 10.3390/ijms25136820.
2
Effect of polyphenols against complications of COVID-19: current evidence and potential efficacy.多酚对新冠并发症的作用：当前证据与潜在疗效
Pharmacol Rep. 2024 Apr;76(2):307-327. doi: 10.1007/s43440-024-00585-6. Epub 2024 Mar 18.
3
Serum Proteome Signatures of Anti-SARS-CoV-2 Vaccinated Healthcare Workers in Greece Associated with Their Prior Infection Status.血清蛋白质组学特征与希腊接受过 SARS-CoV-2 疫苗接种的医护人员的既往感染状况相关。
Int J Mol Sci. 2022 Sep 5;23(17):10153. doi: 10.3390/ijms231710153.

本文引用的文献

1
Mucoadhesive nanoformulations and their potential for combating COVID-19.黏膜黏附纳米制剂及其对抗COVID-19的潜力。
Nanomedicine (Lond). 2021 Dec;16(28):2497-2501. doi: 10.2217/nnm-2021-0287. Epub 2021 Nov 3.
2
O-Glycosylation Landscapes of SARS-CoV-2 Spike Proteins.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白的O-糖基化图谱
Front Chem. 2021 Sep 6;9:689521. doi: 10.3389/fchem.2021.689521. eCollection 2021.
3
Complement activation and increased expression of Syk, mucin-1 and CaMK4 in kidneys of patients with COVID-19.新型冠状病毒肺炎患者肾脏中补体激活以及脾酪氨酸激酶、黏蛋白-1和钙/钙调蛋白依赖性蛋白激酶4表达增加。
Clin Immunol. 2021 Aug;229:108795. doi: 10.1016/j.clim.2021.108795. Epub 2021 Jul 10.
4
Cytokine Storm and Mucus Hypersecretion in COVID-19: Review of Mechanisms.新冠病毒肺炎中的细胞因子风暴与黏液高分泌：机制综述
J Inflamm Res. 2021 Jan 22;14:175-189. doi: 10.2147/JIR.S271292. eCollection 2021.
5
Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy.针对环氧化酶酶的 COVID-19 辅助治疗。
Drug Dev Res. 2021 Jun;82(4):469-473. doi: 10.1002/ddr.21794. Epub 2021 Jan 25.
6
Mucin signature as a potential tool to predict susceptibility to COVID-19.黏蛋白标志物可作为预测 COVID-19 易感性的潜在工具。
Physiol Rep. 2021 Jan;9(1):e14701. doi: 10.14814/phy2.14701.
7
Morphogenetic (Mucin Expression) as Well as Potential Anti-Corona Viral Activity of the Marine Secondary Metabolite Polyphosphate on A549 Cells.海洋次生代谢产物多聚磷酸盐对 A549 细胞的形态发生（粘蛋白表达）和潜在的抗冠状病毒活性。
Mar Drugs. 2020 Dec 14;18(12):639. doi: 10.3390/md18120639.
8
A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury.一项针对降低黏蛋白-1化合物的高内涵筛选将福他替尼鉴定为急性肺损伤快速重新利用的候选药物。
Cell Rep Med. 2020 Oct 29;1(8):100137. doi: 10.1016/j.xcrm.2020.100137. eCollection 2020 Nov 17.
9
Mucus production stimulated by IFN-AhR signaling triggers hypoxia of COVID-19.IFN-AhR 信号刺激黏液产生引发 COVID-19 缺氧。
Cell Res. 2020 Dec;30(12):1078-1087. doi: 10.1038/s41422-020-00435-z. Epub 2020 Nov 6.
10
COVID-19 vaccines: early success and remaining challenges.新冠疫苗：早期成效与尚存挑战
Lancet. 2020 Sep 26;396(10255):868-869. doi: 10.1016/S0140-6736(20)31867-5. Epub 2020 Sep 4.

Targeting mucin hypersecretion in COVID-19 therapy.

作者信息

Prasher Parteek, Sharma Mousmee

机构信息

Department of Chemistry, UGC Sponsored Centre for Advanced Studies, Guru Nanak Dev University, Amritsar, 143005, India.

Department of Chemistry, University of Petroleum & Energy Studies, Energy Acres, Dehradun, 248007, India.

出版信息

Future Med Chem. 2022 May;14(10):681-684. doi: 10.4155/fmc-2021-0111. Epub 2022 Mar 22.

DOI:10.4155/fmc-2021-0111
PMID:35315705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8939459/
Abstract
摘要